# Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00268216** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 6228 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Salmeterol 50mcg/ Fluticasone Propionate 500mcg

## Key facts

- **NCT ID:** NCT00268216
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 6228 (ACTUAL)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00268216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00268216, "Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00268216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*